D'Orazio & Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

D'Orazio & Associates’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$15K	–	786
2021 Q2	$15K	Hold	500	–	–	﹤0.01%	282
2021 Q1	$13K	Hold	500	–	–	﹤0.01%	272
2020 Q4	$13K	Hold	500	–	–	﹤0.01%	260
2020 Q3	$10K	Hold	500	–	–	﹤0.01%	230
2020 Q2	$12K	Hold	500	–	–	0.01%	228
2020 Q1	$9K	Hold	500	–	–	﹤0.01%	232
2019 Q4	$12K	Hold	500	–	–	﹤0.01%	239
2019 Q3	$14K	Hold	500	–	–	﹤0.01%	232
2019 Q2	$17K	Buy	+500	New	+$17.1K	﹤0.01%	212

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

D'Orazio & Associates's SUPN Position: Q3 2021 in Review

D'Orazio & Associates sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 500 shares — an estimated $15K sold.

D'Orazio & Associates first reported a position in SUPN in Q2 2019 and held it in 9 quarters. The position peaked at $17K in Q2 2019. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

D'Orazio & Associates reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
D'Orazio & Associates sold 500 Supernus Pharmaceuticals shares in Q3 2021, an estimated $15K.
D'Orazio & Associates first reported a position in Supernus Pharmaceuticals in Q2 2019 and held it in 9 quarters.
D'Orazio & Associates's Supernus Pharmaceuticals position peaked at $17K in Q2 2019.
223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on D'Orazio & Associates's 13F filing for Q3 2021, filed 10 Nov 2021.